Editas Medicine Announces Second Quarter 2019 Results and Update

    NEXT STORY
    Opthea Meets Primary Endpoint in Phase 2b Study of OPT-302 in Wet AMD
    PREV STORY
    Turning Point Therapeutics Reports Second Quarter 2019 Financial and Operational Results
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    ImCheck Achieves Initial Positive Independent Safety Review and Initiates Next Stage of Phase I/IIa EVICTION Trial for ICT01

    author_avatar
    NASDAQ Market News

    Chi-Med to Present at the 37th Annual JP Morgan Healthcare Conference

    LONDON, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) ...

    author_avatar
    NASDAQ Market News

    Emerald Health Therapeutics Joint Venture Launches Cannabis-Free Endocannabinoid-Supporting Health Supplement in Canada

    author_avatar
    NASDAQ Market News